Animal Pharmaceuticals

dc.contributor.author	Terry, Martin
dc.date.accessioned	2017-05-17T18:54:34Z
dc.date.available	2017-05-17T18:54:34Z
dc.date.issued	1992
dc.description.abstract	The regulatory agencies consider oversight as appropriately applied in direct proportion to the risk associated with a given product per se, independent of the technology employed in the manufacturing process. FDA cannot legally take socioeconomic considerations into ac-count in the premarket drug approval process; animal drugs must be evaluated on the basis of the objective criteria of safety and efficacy. However, FDA does not operate in a political vacuum and in a situation where heated political debates on the socioeconomic aspects of a new animal drug run concurrently with the regulatory evaluation of the drug, it is hard to believe that the agency would not be affected to some degree in its deliberations on the drug.
dc.identifier.uri	https://hdl.handle.net/1813/49752
dc.language.iso	en_US
dc.publisher	NABC
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Agricultural biotechnology
dc.subject	animal biotechnology
dc.subject	bioethics
dc.subject	animal well-being
dc.subject	food safety
dc.subject	science communication
dc.subject	agricultural indistry
dc.subject	consumers sentimen
dc.subject
dc.title	Animal Pharmaceuticals
dc.type	book chapter

Files

Now showing 1 - 1 of 1